Note: This article does not constitute any investment opinions and suggestions, and official/company announcements shall prevail; this article is only an introduction to medical and health-related drugs, not a recommendation for treatment plans (if involved), and does not represent the position of the platform. Reprinting of any article requires authorization.
Recently, Yiming (Beijing) Cell Biotechnology Co., Ltd. (hereinafter referred to as Yiming Cell) announced that it has officially appointed Dr. Chen Ying as chief scientific officer (CSO). Dr. Chen Ying will be fully responsible for the work of Yiming Cell Global R&D Center, mainly conducting iterative research and development of basic and forward-looking new technology products, including AAV serotype screening, stable transfection strain platform process development, etc., to ensure that Yiming Cell Technology is ranked first in the world. The first echelon leads the development trend of the industry, promotes Yiming Cells to a higher level in the CDMO field of CGT, and provides better services to more CGT new drug companies around the world.
Dr. Chen Ying Chief Scientific Officer of Yiming Cells
Dr. Chen Ying is a well-known expert in the fields of neurocytology and viral vectors. He studied in the Department of Biology of Peking University for his bachelor's and master's degrees under the tutelage of Academician of the Chinese Academy of Sciences Professor Zhai Zhonghe . Later, he received a PhD in neuroscience from Johns Hopkins University. During his postdoctoral research in the laboratory of Academician Ho Zhigang (a member of the National Academy of Medicine) at Harvard University Children's Hospital, he focused on the protection of damaged nerve cells and methods related to nerve cell regeneration. Research on signal transduction and achieved fruitful results.
Dr. Chen Ying has been engaged in the field of gene therapy viral vector development since entering the biological industry. She has successively held important positions such as R&D scientist, R&D senior scientist, and R&D director in internationally renowned biological companies. Since 2012, he has co-founded Vigene Biosciences, Inc, as one of the co-founders, and has successively served as the company's president of R&D and production, leading Vigene to become one of the first companies in North America to engage in commercial production of AAV, and leading Vigene to become a world-renowned company. Gene therapy product CDMO service provider. Vigene was acquired by Charlies River, a world-renowned CRO company, in May 2021.
Dr. Chen Ying has extensive experience in gene editing fields such as TALEN and CRISPR/Cas9, and has published more than 10 papers in Cell, Cancer Res and other magazines. Since 2017, Dr. Chen Ying has served as the technical president of Vigene China, leading the team to establish multiple human gene spot libraries - 18,000 ORF clones, 12,000 ORF adenovirus, more than 1,200 miRNA clones, adenovirus and more than 320 gRNA pool clones. In addition, we have completed more than 12,500 mouse gRNA pool clones, more than 100 monoclonal knockout HEK293 cell lines of tumor disease-related genes, and more than 400 adeno-associated viruses/adenoviruses/ lentivirus in stock, achieving 50% annual sales. Amount growth.
Dr. Sun Xiulian, Chairman and Chief Technology Officer of Yiming Cell, representative team warmly welcomed Dr. Chen Ying to join. She said: "The continuous progress of science and technology is the driving force of development. Basic and forward-looking research and development determine the company's technical strength. The CSO is directly related to the company's future development process. Dr. Chen Ying has global influence in the fields of neuroscience and CGT's CDMO. His years of experience and strong professional knowledge, especially in the field of AAV, can be quickly and effectively implemented. Injecting it into all business areas of the company, from R&D to market, will comprehensively enhance the company's pioneering and innovative capabilities. Dr. Chen Ying's joining will also greatly promote the international construction and global development of Yiming Cells and promote the company's internationalization process. Dr. Ying will play an important role in the rapid development of Yiming Cell, accelerate the creation of a world-class CDMO platform, and provide better services to global customers."
Dr. Chen Ying said: "With the rapid heating up of the entire CGT industry, the importance of the company is increasing. The demand for gene therapy outsourcing services is also growing. As a CDMO service provider, Yiming Cell has been deeply involved in the CGT field for many years. It has a first-class professional team, efficient platform technology, and a complete quality control and quality inspection system, and has provided comprehensive services to dozens of domestic and foreign CGT companies. New drug companies provide one-stop overall solutions.In the prosperous era of the CGT industry, it is my honor to lead the team to join Yiming Cell. I will give full play to my knowledge and rich experience in this field, and work with everyone to improve the company's scientific research level and business quality, and do a good job in the European and American markets. expansion to better serve new and old customers, so that good medicines can benefit patients as soon as possible. "
It is reported that Dr. Chen Ying will give a wonderful report at the 2022 CGT "Yiqi Create the Future" Summit Forum and the opening ceremony of Yiming Cell Suzhou CDMO New Base on July 15th, so stay tuned.
This meeting will be hosted by The forum is organized by Yiming Cell and iMic, aiming to promote the development of the CGT industry and serve CGT new drug research and development companies as much as possible. The forum will invite domestic and foreign front-line cell and gene therapy industry and clinical experts to focus on the latest research trends and progress of gene therapy. The clinical supervision of gene therapy, treatment specifications, cell therapy safety and other issues of concern in the industry are fully discussed.
About Yiming Cells
Yiming Cell Biotechnology Co., Ltd. (referred to as: Yiming Cell) is a company dedicated to cell and gene therapy technology.
A R&D and production biotechnology company that provides overall solutions for the industrialization of gene therapy. Since its establishment, Yiming Cell has deployed global AAV gene therapy and cell therapy research and development, and has gradually formed and upgraded its products from large-scale plasmid . , AAV and other vector preparation, to quality monitoring and testing (including empty shell rate, virus infection titer , host protein, virus particle aggregation degree, etc.), to process development and optimization, formula development and trial production services, etc. A complete set of platform technology. The Suzhou base delivered in March this year further expanded the capabilities and scale of Yiming Cell's high-quality CDMO platform.
Yiming Cell has established R&D centers in North America (Vancouver, Canada, and Maryland, USA), with Suzhou and Jinan has built a GMP factory with an area of more than 10,000 square meters, using absolute A-class isolator filling, and invited well-known experts to build the GMP system. In accordance with regulatory requirements, it has built an independent plasmid production platform, virus packaging platform, cell culture platform, cell Library platform, etc., and has a quality testing platform covering biochemistry, microbiology, and chemistry. Currently, it can provide GMP-level AAV, plasmid, lentivirus, adenovirus, CAR-T and other viral vectors and gene drugs to cell and gene therapy companies. Development and preparation services, as well as supporting product process development solutions, GMP system translation and other services, provide comprehensive one-stop CDMO solutions to customers in the field of cell and gene therapy to assist customers in accelerating the development of gene cell drugs in China, the United States, Europe and other countries R&D, clinical trials and launch.
With the original intention and persistence, Yiming Cell will continue to practice its original intention and bring good medicine to patients faster!
Ubrigene, Serve with hearts!
